Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan, Kelly P. Burke, Eliezer M. Van Allen
Nature Medicine (2019) Vol. 25, Iss. 3, pp. 389-402
Open Access | Times Cited: 412

Showing 1-25 of 412 citing articles:

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi, Robert Yuan, Edgar G. Engleman
Annual Review of Pathology Mechanisms of Disease (2020) Vol. 16, Iss. 1, pp. 223-249
Open Access | Times Cited: 1536
Immunotherapies for hepatocellular carcinoma
Josep M. Llovet, Florian Castet, Mathias Heikenwälder, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 3, pp. 151-172
Closed Access | Times Cited: 1150
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Patrick Y. Wen, Michael Weller, Eudocia Q. Lee, et al.
Neuro-Oncology (2020) Vol. 22, Iss. 8, pp. 1073-1113
Open Access | Times Cited: 818
RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore, Scott Rosenberg, Frank McCormick, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 8, pp. 533-552
Open Access | Times Cited: 807
Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma
Andrew L. Ji, Adam J. Rubin, Kim Thrane, et al.
Cell (2020) Vol. 182, Iss. 2, pp. 497-514.e22
Open Access | Times Cited: 774
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
Eryn Blass, Patrick A. Ott
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 4, pp. 215-229
Open Access | Times Cited: 721
Intratumoral heterogeneity in cancer progression and response to immunotherapy
Ilio Vitale, Efrat Shema, Sherene Loi, et al.
Nature Medicine (2021) Vol. 27, Iss. 2, pp. 212-224
Closed Access | Times Cited: 560
Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes
Ekaterina Friebel, Konstantina Kapolou, Susanne Unger, et al.
Cell (2020) Vol. 181, Iss. 7, pp. 1626-1642.e20
Open Access | Times Cited: 508
The SWI/SNF complex in cancer — biology, biomarkers and therapy
Priya Mittal, Charles W.M. Roberts
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 7, pp. 435-448
Open Access | Times Cited: 460
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Mengyu Chang, Zhiyao Hou, Man Wang, et al.
Advanced Materials (2020) Vol. 33, Iss. 4
Closed Access | Times Cited: 345
Beyond immune checkpoint blockade: emerging immunological strategies
Shawn P. Kubli, Thorsten Berger, Daniel Vilarim Araújo, et al.
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 12, pp. 899-919
Closed Access | Times Cited: 332
Organoids in immunological research
Yotam E. Bar‐Ephraïm, Kai Kretzschmar, Hans Clevers
Nature reviews. Immunology (2019) Vol. 20, Iss. 5, pp. 279-293
Open Access | Times Cited: 267
Ovarian Cancer Immunotherapy and Personalized Medicine
Susan Morand, Monika Devanaboyina, Hannah Staats, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 12, pp. 6532-6532
Open Access | Times Cited: 243
Dynamics and specificities of T cells in cancer immunotherapy
Giacomo Oliveira, Catherine J. Wu
Nature reviews. Cancer (2023) Vol. 23, Iss. 5, pp. 295-316
Closed Access | Times Cited: 222
Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients
Michael J. Duffy, John Crown
Clinical Chemistry (2019) Vol. 65, Iss. 10, pp. 1228-1238
Open Access | Times Cited: 209
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation
Elizabeth Paver, Wendy A. Cooper, Andrew J. Colebatch, et al.
Pathology (2020) Vol. 53, Iss. 2, pp. 141-156
Closed Access | Times Cited: 197
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
Mihaela Aldea, Fabrice André, Aurélien Marabelle, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 874-899
Open Access | Times Cited: 180
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
Breelyn A. Wilky
Immunological Reviews (2019) Vol. 290, Iss. 1, pp. 6-23
Closed Access | Times Cited: 176
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Diego Chowell, Seong‐Keun Yoo, Cristina Valero, et al.
Nature Biotechnology (2021) Vol. 40, Iss. 4, pp. 499-506
Open Access | Times Cited: 173
Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
Jackson G. Egen, Wenjun Ouyang, Lawren C. Wu
Immunity (2020) Vol. 52, Iss. 1, pp. 36-54
Open Access | Times Cited: 165
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Carla Montironi, Florian Castet, Philipp K. Haber, et al.
Gut (2022) Vol. 72, Iss. 1, pp. 129-140
Open Access | Times Cited: 158
Spatial CRISPR genomics identifies regulators of the tumor microenvironment
Maxime Dhainaut, Samuel A. Rose, Güray Aktürk, et al.
Cell (2022) Vol. 185, Iss. 7, pp. 1223-1239.e20
Open Access | Times Cited: 149
FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
Ye Wang, Zhuang Tong, Wen‐Hua Zhang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 147
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials
Khalil Choucair, Susan Morand, Laura Stanbery, et al.
Cancer Gene Therapy (2020) Vol. 27, Iss. 12, pp. 841-853
Closed Access | Times Cited: 143
Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy
Qinghua Wang, Meiling Li, Meng Yang, et al.
Aging (2020) Vol. 12, Iss. 4, pp. 3312-3339
Open Access | Times Cited: 139
Page 1 - Next Page

Scroll to top